1. Home
  2. PDYNW vs CMMB Comparison

PDYNW vs CMMB Comparison

Compare PDYNW & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Palladyne AI Corp

PDYNW

Palladyne AI Corp

HOLD

Current Price

$0.08

Market Cap

0.0

Sector

Industrials

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

HOLD

Current Price

$2.22

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDYNW
CMMB
Founded
2017
2004
Country
United States
Israel
Employees
70
N/A
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
13.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PDYNW
CMMB
Price
$0.08
$2.22
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$26.50
AVG Volume (30 Days)
210.9K
93.1K
Earning Date
02-28-2025
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,771,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$2.21
52 Week High
$0.54
$9.84

Technical Indicators

Market Signals
Indicator
PDYNW
CMMB
Relative Strength Index (RSI) 35.13 35.70
Support Level $0.08 $2.44
Resistance Level $0.09 $2.77
Average True Range (ATR) 0.02 0.19
MACD 0.00 -0.01
Stochastic Oscillator 14.81 1.79

Price Performance

Historical Comparison
PDYNW
CMMB

About PDYNW Palladyne AI Corp

Palladyne AI Corp is a software company focused on autonomy for robotic systems and solutions. Its artificial intelligence and machine learning software seeks to revolutionize the capabilities of robots, enabling them to observe, learn, reason, and act in structured and unstructured environments. AI and ML software platform of the company empowers robots to perceive variations or changes in the real-world environment, enabling them to autonomously maneuver and manipulate objects accurately in response. Palladyne AI software has wide application, including in industries such as automotive, aviation, construction, defense, general manufacturing, infrastructure inspection, logistics and warehousing.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Share on Social Networks: